11/02/2019 17:14:26

C-Bridge Capital Forms AffaMed Therapeutics to Accelerate Commercialization of Biologics in China

SHANGHAI, China, Feb. 11, 2019 (GLOBE NEWSWIRE) -- AffaMed Therapeutics, a new biopharmaceutical company founded and funded by C-Bridge Capital, a healthcare private equity firm focused on the development and late-stage investment opportunities, announced today that it is partnering with Samsung Bioepis to accelerate the commercialization of multiple next-generation biosimilars in China. Pharmaceutical industry veteran, Dr. Nathan Pang, will lead the Company as CEO.

The licensed products include SB3 referencing trastuzumab (Herceptin®), which received approval from the U.S. Food & Drug Administration (FDA) and European Medicines Agency for sale in the European Union, SB11 referencing ranibizumab (Lucentis®), which is currently undergoing Phase 3 trials in the U.S and SB12 referencing eculizumab (Soliris®).

“Dr. Pang’s deep industry knowledge and extensive leadership skills will be invaluable as the company develops and expands its portfolio of products,” said Dr. Michael Keyoung, M.D., Ph.D., Chair of the Board of Directors at AffaMed and Managing Director at C-Bridge Capital. “His previous leadership roles coupled with his expertise of the biopharmaceutical industry make him well suited to lead AffaMed.”

Dr. Pang has more than 20 years of experience as a physician and a healthcare executive. Prior to joining AffaMed Therapeutics, he was the General Manager of Sanofi Pasteur China, where he expanded the company’s pipeline by securing licensing agreements with Janssen China and Merck (MSD) China. Before that, he was the CEO of Sandoz China, the Generics Division of Novartis Group, during which he started up and grew the business to an organization with commercialised portfolio and profitable revenue. Previously, he was the Asia Pacific Regional Head for the Novartis Oncology Business Unit overseeing 14 countries in Asia including China. Dr. Pang holds a Bachelor of Medicine; Bachelor of Surgery (M.B.B.S) from the National University of Singapore and Bachelor of Law from the University of London, as well as a dual EMBA from France’s INSEAD and China’s Tsinghua University.

“We are thrilled to partner with Samsung Bioepis, a proven leader in the global biosimilar industry, to develop these next-generation biologic candidates for patients in China,” Dr. Pang said. “Our team’s clinical, regulatory and commercial experience with innovative biologics makes AffaMed uniquely suited to advance the development and registration of these products in China.”

About AffaMed Therapeutics

AffaMed Therapeutics is a biopharmaceutical company focused on identifying and licensing late-stage candidates for commercialization in emerging Asia Pacific markets and globally. AffaMed was founded and funded by C-Bridge Capital in 2019.

About C-Bridge Capital

C-Bridge Capital is a healthcare dedicated private equity firm, focused on growth and late-stage investment opportunities across the healthcare industry. C-Bridge Capital is committed to supporting the commercialization of cutting-edge technologies and companies that fulfil unmet medical needs, thus continuously improving the standard and quality of care for patients.

Contacts:

Media in US and Europe:

James Heins

Senior Vice President

Westwicke PR, an ICR Company

Tel. +1 203-682-8251

James.Heins@icrinc.com

Media in Asia:

Edmond Lococo

Senior Vice Present

ICR Asia

+86(10) 6583-7510

Edmond.lococo@icrinc.com

logo-c.jpg

Del

Post comment

Related debate

  • 1 week
  • 1 month
  • 1 Year
18 Apr
I:SP500
  Hejsa.   Lige lidt læsestof til påsken.   Langsigtet konjunktur:   Overraskende stigning i de le..
48
18 Apr
 
Jeg har modtaget flg. fra Delfin : "Nå, så er jeg blokeret på EI. Hvorfor ved jeg ikke. Jeg har ikke..
39
17 Apr
VELO
  Den eneste TA-ekspert var for mig alpehue, og nogle ganske få andre. Langt de fleste, som udtaler ..
28
20 Apr
NOVO-B
En lille påskehilsen fra Alpe, med mulighed for Novo.   https://invst.ly/al3nf  
23
17 Apr
 
EI hvorfor har I slettet mit indlæg 414414 og hele debatten om hvad en moderater bør blande sig i ? ..
21
21 Apr
NOVO-B
Det var bare mig, der havde spurgt Alpe om en streg på Novo, hvorefter jeg modtog dette, og gerne må..
20
21 Apr
NOVO-B
Er du dum, VI VIL HAVE ALPE TILBAGE
11
17 Apr
TEVA
Den er også svær lige nu fordi mange korte og lange signaler krydser ind over hinanden lige nu. Men ..
11
15 Apr
VWS
Vestas i 600.. 😊 Det er en stor dag... Tillykke til de tålmodige og trofaste aktionærer.. Endelig ..
11
20 Apr
ZEAL
Nedenfor er en artikle fra Ritzau fra 2018 som gennemgår situationen med Zealand Pharmas tyske samar..
10

#

EuroInvestor: In Focus
#

#

EuroInvestor: In Focus
#

#

EuroInvestor: In Focus
#

Most read news

  • 24 hours
  • 48 hours
  • 1 week
1
Start of Day Message
2
Nevada Joint Venture Deal Clears All Regulatory Conditions
3
Franklin Electric Declares Payment of Quarterly Cash Dividend
4
Molecular Templates Announces FDA Acceptance of IND Application for MT-5111, An Engineered Toxin Body Targeting HER2
5
BoxScore Brands Board of Directors Announces the Addition of Consumer Products Veteran Michael P. Flanagan as CEO and Member of the Board of Directors as Well as a New Strategic Direction

Latest news


Copyright Berlingske Media 2019  Cookie- and Privacy policy  |  Cookies  |   General terms of trade  |   Terms of use and IP rights
Quote information is delivered by Morningstar.
Data is delayed 15-20 minutes according to the distribution agreements set by the different exchanges.
 
22 April 2019 17:51:46
(UTC+00:00) Dublin, Edinburgh, Lisbon, London
Version: LiveBranchBuild_20190410.2 - EUROWEB7 - 2019-04-22 18:51:46 - 2019-04-22 17:51:46 - 1000 - Website: OKAY